KR20260018203A - 시알리다제-내성 당류 및 이의 제조 및 사용 방법 - Google Patents

시알리다제-내성 당류 및 이의 제조 및 사용 방법

Info

Publication number
KR20260018203A
KR20260018203A KR1020267002768A KR20267002768A KR20260018203A KR 20260018203 A KR20260018203 A KR 20260018203A KR 1020267002768 A KR1020267002768 A KR 1020267002768A KR 20267002768 A KR20267002768 A KR 20267002768A KR 20260018203 A KR20260018203 A KR 20260018203A
Authority
KR
South Korea
Prior art keywords
mmol
equiv
compound
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267002768A
Other languages
English (en)
Korean (ko)
Inventor
치-휘 웅
홍-제이 로
Original Assignee
아카데미아 시니카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카데미아 시니카 filed Critical 아카데미아 시니카
Publication of KR20260018203A publication Critical patent/KR20260018203A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020267002768A 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법 Pending KR20260018203A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962829736P 2019-04-05 2019-04-05
US62/829,736 2019-04-05
KR1020217031324A KR102920761B1 (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법
PCT/US2020/014608 WO2020205034A1 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031324A Division KR102920761B1 (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법

Publications (1)

Publication Number Publication Date
KR20260018203A true KR20260018203A (ko) 2026-02-06

Family

ID=72666761

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267002768A Pending KR20260018203A (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법
KR1020217031324A Active KR102920761B1 (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217031324A Active KR102920761B1 (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법

Country Status (9)

Country Link
US (2) US12384811B2 (https=)
EP (1) EP3947406A4 (https=)
JP (2) JP7621270B2 (https=)
KR (2) KR20260018203A (https=)
CN (1) CN115605491B (https=)
CA (1) CA3131096A1 (https=)
IL (1) IL286492B1 (https=)
TW (1) TWI749504B (https=)
WO (1) WO2020205034A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812695A (ja) * 1994-06-30 1996-01-16 Nisshin Oil Mills Ltd:The 新規シアル酸供与体
US7569376B2 (en) 2002-05-03 2009-08-04 Neose Technologies, Inc. Fucosyltransferase fusion protein
CA2441677A1 (en) 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus
US20090214590A1 (en) 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DK3438131T3 (da) 2006-02-10 2022-04-11 Life Technologies Corp Oligosaccharidmodifikation og mærkning af proteiner
PT2170365T (pt) 2007-06-25 2016-07-12 Autoimmune Tech Llc Composições e métodos inibidores de influenza
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
HUE039100T2 (hu) 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
US20130005797A1 (en) 2010-03-18 2013-01-03 Merck Sharp & Dohme Corp. Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
EP2654787A1 (en) 2010-12-22 2013-10-30 Novavax, Inc. Modified influenza hemagglutinin proteins and uses thereof
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013067652A1 (en) 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
WO2014055474A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2015031166A1 (en) 2013-08-26 2015-03-05 Fred Hutchinson Cancer Research Center Compositions and methods for directed immunogen evolution and uses thereof
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
US10421802B2 (en) 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
CN105934441A (zh) 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
WO2015142671A2 (en) 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2017062496A2 (en) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
KR101873527B1 (ko) * 2016-09-02 2018-07-02 부산대학교 산학협력단 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3056206A1 (en) 2017-03-15 2018-09-20 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
US20200231633A1 (en) 2017-07-19 2020-07-23 The Regents Of The University Of California MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
AU2018312563A1 (en) 2017-08-01 2020-03-12 City Of Hope Anti-IL1RAP antibodies
CN111770991A (zh) 2017-12-18 2020-10-13 通用医疗公司 糖工程
US11191777B2 (en) 2018-06-20 2021-12-07 International Business Machines Corporation Antimicrobial guanidinium macromolecules with bacteria targeting moieties
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110713537B (zh) 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
KR20210061393A (ko) 2018-09-18 2021-05-27 유니버시테이트 젠트 치료용 나노입자 및 이의 사용 방법
WO2020077159A1 (en) 2018-10-10 2020-04-16 The Johns Hopkins University POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY
WO2020172072A1 (en) 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
WO2020198865A1 (en) 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
GB201908352D0 (en) 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
FR3098110B1 (fr) 2019-07-03 2022-02-04 Chanel Parfums Beaute Composition cosmétique solide
BR112022001185A2 (pt) 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR102019017792A2 (pt) 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
US20220387461A1 (en) 2019-09-04 2022-12-08 Victoria Link Ltd Cancer vaccine
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021174128A1 (en) 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
IL296426A (en) 2020-03-19 2022-11-01 Baseclick Gmbh Maran"im that underwent a change for the development of a component
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
RU2720614C9 (ru) 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
KR20230005962A (ko) 2020-05-01 2023-01-10 니코데 테라퓨틱스 에이에스에이 베타코로나바이러스 예방 및 치료요법
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
IL298333A (en) 2020-05-20 2023-01-01 Alexandru Adrian Hennrich A viral assembly vector for a vaccine against the corona virus cell
CN116322732A (zh) 2020-06-17 2023-06-23 迪斯拉普申实验室公司 用治疗剂补充产品的组合物及其使用方法
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
RU2730897C1 (ru) 2020-07-01 2020-08-26 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) СПОСОБ ИСПОЛЬЗОВАНИЯ РЕКОМБИНАНТНЫХ БЕЛКОВ SARS-COV-2 В СОСТАВЕ ТЕСТ-СИСТЕМЫ ДЛЯ ИММУНОФЕРМЕНТНОГО АНАЛИЗА С ОПРЕДЕЛЕНИЕМ УРОВНЕЙ АНТИТЕЛ КЛАССОВ IgM, IgG, IgA В СЫВОРОТКЕ/ПЛАЗМЕ КРОВИ БОЛЬНЫХ COVID-19
WO2022047401A1 (en) 2020-08-31 2022-03-03 The University Of Chicago Targeted, intracellular delivery of therapeutic peptides using supramolecular nanomaterials
CN112626124B (zh) 2020-10-15 2023-04-11 广州达博生物制品有限公司 一种病毒保存试剂
BR112023005961A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Molécula de ácido nucleico modificada, vacina combinada, nanopartícula, nanocluster de mrna, método para prevenir ou tratar uma infecção por coronavírus, método para reforço de uma resposta imune adaptativa, peptídeo imunogênico e composição imunogênica
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
JP2024517711A (ja) 2021-04-29 2024-04-23 ノバルティス アーゲー 高シアル酸付加細胞
CN113265050B (zh) 2021-04-30 2022-08-23 浙江大学 一种可降解高分子材料和自组装纳米复合物及应用
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
US20250195639A1 (en) 2021-10-20 2025-06-19 The Regents Of The University Of California Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes
WO2023129928A2 (en) 2021-12-27 2023-07-06 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
CN116478948A (zh) 2023-03-01 2023-07-25 中山大学 一种生成高唾液酸化蛋白药物的细胞工程方法
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
WO2024215616A2 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting vaccines
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Also Published As

Publication number Publication date
US20220267363A1 (en) 2022-08-25
WO2020205034A1 (en) 2020-10-08
US12384811B2 (en) 2025-08-12
JP2022529408A (ja) 2022-06-22
IL286492A (en) 2021-12-01
CA3131096A1 (en) 2020-10-08
TW202104272A (zh) 2021-02-01
US20260008803A1 (en) 2026-01-08
KR102920761B1 (ko) 2026-02-02
KR20210137485A (ko) 2021-11-17
EP3947406A1 (en) 2022-02-09
TWI749504B (zh) 2021-12-11
IL286492B1 (en) 2026-04-01
JP7621270B2 (ja) 2025-01-24
JP2025063181A (ja) 2025-04-15
CN115605491A (zh) 2023-01-13
CN115605491B (zh) 2026-03-24
EP3947406A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
KR102920761B1 (ko) 시알리다제-내성 당류 및 이의 제조 및 사용 방법
Kondo et al. Glycosyl phosphites as glycosylation reagents: scope and mechanism
US10266502B2 (en) Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
US12281135B2 (en) Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate
EP2935608A1 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2012135049A1 (en) Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
Cattaneo et al. Orthogonal cleavage of the 2-naphthylmethyl group in the presence of the p-methoxy phenyl-protected anomeric position and its use in carbohydrate synthesis
Datta et al. An improved synthesis of trehalose 6-mono and 6, 6′-dicorynomycolates and related esters
EP4585601A1 (en) Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
EP3097200A1 (en) Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
JPH10502093A (ja) レジオ選択的硫酸化
WO2022191313A1 (ja) 糖鎖及び糖鎖を含む医薬品の製造方法
WO2023074843A1 (ja) 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法
Caravano et al. Developing an asymmetric, stereodivergent route to selected 6-deoxy-6-fluoro-hexoses
JP6198207B2 (ja) 新規糖供与体及びそれを用いた糖鎖の合成方法
CN106632518A (zh) 一种鬼臼毒素4‑oh衍生物的制备方法
JP2001348396A (ja) リピッドａ１位カルボキシメチル類縁体
CN1334268A (zh) 一种可作药用的阿拉伯－半乳多糖的活性四糖片段的合成
Wu S nthesis and immunological e aluation of Pel and Psl gl cocon ugate accine candidates against Pseudomonas aeruginosa
Banerjee Stereoselective glycosylation and chemical ligation-applications in oligosaccharide and peptide synthesis
Kov&E et al. Laboratory of Medicinal Chemistry, NIDDK, Bldg. 8, Rm. B1-23, National Institutes of Health, Bethesda, MD 20892-0815, USA.
JPWO2017154938A1 (ja) 硫酸基および／またはリン酸基を有する糖の製造方法

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000